<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979052</url>
  </required_header>
  <id_info>
    <org_study_id>HDM-FUN-Candidemia</org_study_id>
    <nct_id>NCT04979052</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia</brief_title>
  <official_title>Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horizon 2020 - European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized open label interventional phase 2 pilot study to evaluate safety and efficacy of&#xD;
      recombinant Interferon-Gamma 1b in patients with candidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized open label interventional phase 2 pilot study of the safety&#xD;
      and efficacy of rIFN-γ in patients with candidemia. Patients will be randomized 1:1 between&#xD;
      intervention (rIFN-y immunotherapy, subcutaneous dose of 100miicrogram thrice weekly for two&#xD;
      weeks or until hospital discharge) in addition to standard of care versus controls (standard&#xD;
      of care). Standard of care antifungal therapy is according to ESCMID/EFISG (Europe) or IDSA&#xD;
      (US) guidelines. We will assess the effect on clinical outcome and investigate relevant&#xD;
      biomarkers that can guide this immunotherapeutic approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, opel label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first negative blood culture</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment success</measure>
    <time_frame>Day 14</time_frame>
    <description>microbiological eradication of Candida from the blood and any other site of infection; resolution of fever; resolution of other diagnostic variables, such as imaging results, where applicable; and no new signs of infection. The time at which all the variables are met is defined as the date of resolution of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with mycological outcomes</measure>
    <time_frame>through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with treatment success</measure>
    <time_frame>through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Study day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Treatment Emergent Adverse Events (TEAEs).</measure>
    <time_frame>Study day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>Study day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Study day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Study day 49</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Study day 49</time_frame>
    <description>kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prealbumin</measure>
    <time_frame>Study day 49</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lymphocytes</measure>
    <time_frame>Study day 49</time_frame>
    <description>10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>Study day 49</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Candidemia</condition>
  <arm_group>
    <arm_group_label>Interferon-Gamma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant Interferon-Gamma 1b combined with standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Gamma-1B</intervention_name>
    <description>100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.</description>
    <arm_group_label>Interferon-Gamma</arm_group_label>
    <other_name>Immukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant females (who must agree to use barrier methods of contraception&#xD;
             during the study therapy period, women of childbearing age must have a negative urine&#xD;
             pregnancy or serum test at baseline).&#xD;
&#xD;
          -  Subjects who are 18 years of age or older.&#xD;
&#xD;
          -  Subjects with at least one positive blood culture isolation of Candida species from a&#xD;
             specimen drawn within 96 hours prior to study entry.&#xD;
&#xD;
          -  Subjects who have clinical evidence of infection sometime within 96 hours prior to&#xD;
             enrolment, including at least one of the following:&#xD;
&#xD;
               -  Temperature &gt;37.8 ˚C on two occasions at least four hours apart or one&#xD;
                  measurement &gt; 38.2 ˚C&#xD;
&#xD;
               -  Systolic blood pressure &lt;90 or a &gt;30 mmHg decrease in systolic blood pressure&#xD;
                  from the subject's normal baseline or the need for vasopressive therapy.&#xD;
&#xD;
               -  Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site&#xD;
                  infected with Candida (e.g. joint, skin, eye, bone, oesophagus).&#xD;
&#xD;
               -  Radiologic findings of invasive candidiasis.&#xD;
&#xD;
          -  Subject or their legal representative must sign a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of allergy or intolerance to rIFN-γ.&#xD;
&#xD;
          -  Subjects with a history of documented epileptic seizures.&#xD;
&#xD;
          -  Subjects with severe liver failure ((&gt;5x upper limit AST or ALT or impaired synthesis&#xD;
             of proteins such as coagulation factors manifested by increased prothrombin time).&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Subjects who are unlikely to survive more than 24 hours.&#xD;
&#xD;
          -  Subjects who have failed previous systemic antifungal therapy for the Candida spp.&#xD;
             infection which is being studied.&#xD;
&#xD;
          -  Subjects who have received more than 72 hours of systemic antifungal therapy for the&#xD;
             current episode, within 96 hours prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank vd Veerdonk, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank vd Veerdonk, Dr.</last_name>
    <phone>0031243618819</phone>
    <email>frank.vandeveerdonk@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John R. Perfect, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Der Johann Wolfgang Von Goethe Universitaet</name>
      <address>
        <city>Frankfurt am main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Vehreschild, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Frank vd Veerdonk, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatea de Medicina si Farmacie luliu Hatieganu</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400348</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Calandra, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interferon Gamma 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

